Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Study Overview

• Status: Completed
• Conditions: Hyperuricemia
• Intervention / Treatment: Dietary supplement: Quevir® (Quercetin Phytosome®); Dietary supplement: Bactoblis®

Detailed Description

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

• Study Type: Observational
• Enrollment (Actual): 161

Contacts and Locations

Study Locations

• Italy
  • Milano, Italy
    • Dr. Buccomino Medical Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Healthy participants visited the nutritional clinics during the COVID-19 pandemic for general health check up to improve their immunological protection against COVID-19 infection.

Description

Inclusion Criteria:

• Healthy adults
• BMI between 18.5 and 29.9 kg/m²
• Non-smoker
• Consumtion of less than 3 units of alcohol per day

Exclusion Criteria:

• - Plasma uric acid concentrations above 7 mg/dL
• Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Supplemental Quercetin group; These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.	Dietary supplement: Quevir® (Quercetin Phytosome®); 500 mg Quevir® (Quercetin Phytosome®) tablet; Other Names: Quevir®
Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group; These participants received orally dissolving Bactoblis® tablet, once daily before bedtime for 90 days. Each Bactoblis® tablet contains at least 1x10⁹ CFU of probiotic S. salivarius K12 (ATCC BAA-1024).	Dietary supplement: Bactoblis®; Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in plasma uric acid level	Supplement effect on plasma uric acid level	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in plasma cholesterol level	Supplement effect on plasma cholesterol level	90 days
Change in plasma triglycerides level	Supplement effect on plasma triglycerides level	90 days
Change in plasma glucose level	Supplement effect on plasma glucose level	90 days
Change in plasma insulin level	Supplement effect on plasma insulin level	90 days
Change in plasma creatine phosphokinase level	Supplement effect on plasma creatine phosphokinase level	90 days
Change in alanine transaminase level	Supplement effect on liver function	90 days
Change in aspartate aminotransferase level	Supplement effect on liver function	90 days
Change in alkaline phosphatase level	Supplement effect on liver function	90 days
Change in gamma-glutamyl transferase level	Supplement effect on liver function	90 days
Change in bilirubin level	Supplement effect on liver function	90 days
Incidence of side effects	Number of patients reporting side effects	90 days

Collaborators and Investigators

• Sponsor: Liaquat University of Medical & Health Sciences
• Collaborators: The University of Urbino Carlo Bo, Italy

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2021
• Primary Completion (Actual): December 31, 2022
• Study Completion (Actual): June 15, 2023

Study Registration Dates

• First Submitted: October 16, 2024
• First Submitted That Met QC Criteria: October 20, 2024
• First Posted (Actual): October 22, 2024

Study Record Updates

• Last Update Posted (Actual): October 29, 2024
• Last Update Submitted That Met QC Criteria: October 27, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Hyperuricemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antioxidants; Protective Agents; Quercetin
• Other Study ID Numbers: 88_18.01.2023_QuercetinFit - A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No